Skip to main content
Clinical Trials/NCT05841836
NCT05841836
Recruiting
Not Applicable

A Prospective, Multi-center, Randomized Controlled, Non-inferiority Clinical Trial of the Safety and Efficacy of the Suture-Mediated Closure System for Percutaneous Closure of the Common Femoral Artery Puncture Site

Zhejiang Zylox Medical Device Co., Ltd.1 site in 1 country228 target enrollmentOctober 26, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Peripheral Arterial Disease
Sponsor
Zhejiang Zylox Medical Device Co., Ltd.
Enrollment
228
Locations
1
Primary Endpoint
Incidence of major complications at the access site
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

This was a prospective, multicenter, randomized, controlled, non-inferiority clinical study with the primary objective of validating the safety and efficacy of the Suture-Mediated Closure System for percutaneous closure of the common femoral artery puncture site.

Detailed Description

This study was a prospective, multicenter, randomized, controlled, non-inferiority clinical trial. It is planned to be conducted in multiple clinical trial institutions and enroll 228 subjects. Eligible subjects were randomly divided into the experimental group or the control group at a ratio of 1:1.

Registry
clinicaltrials.gov
Start Date
October 26, 2022
End Date
July 30, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Zhejiang Zylox Medical Device Co., Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Between 18 years old and 85 years old, randomized
  • Patients who can be examined or treated with a common femoral artery puncture interventional catheter using a 5F to 22F sheath tube
  • Patient(or their guardians) who submitted a written informed consent for the this trial

Exclusion Criteria

  • Known to be pregnant or lactating
  • The diameter of femoral artery on the puncture side was less than 5mm
  • Patients requiring anterograde puncture approach
  • Have participated in or plan to participate in another clinical trial in the same period
  • Known allergy to any components of the device, and/or contraindications to contrast agents and anticoagulants
  • International normalized ratio (INR) \>2.0
  • Traumatic vascular injury at the approach site
  • Systemic or local groin infection
  • Cerebrovascular accident or myocardial infarction within 3 months
  • An arterial catheter needs to be placed at the access site

Outcomes

Primary Outcomes

Incidence of major complications at the access site

Time Frame: 30 days after the procedure

The number of subjects who experienced major complications as a proportion of the total number of subjects who used the vascular stapler system

Study Sites (1)

Loading locations...

Similar Trials